¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"non proprietary name"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non-neurogenic neurogenic bladder
    ºñ½Å°æ½Å°æ¼º¹æ±¤
  • non-neurogenic neuropathic bladder
    ºñ½Å°æ½Å°æº´¼º¹æ±¤
  • non-Q wave
    ºñQÆÄ
  • non-rapid eye movement
    ºñ±Þ¼Ó¾È±¸¿îµ¿
  • non-small cell carcinoma
    ºñ¼Ò¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non-Hodgkin lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • non-rapid eye movement
    ºñ±Þ¼Ó¾È±¸¿îµ¿
  • non compos mentis
    ½É½Å»ó½Ç»óÅÂ
  • non-lysosomal proteinase
    ºñ¸®¼Ò¼Ø´Ü¹éºÐÇØÈ¿¼Ò
  • non-vibrating tinnitus
    ºñÁøµ¿±Í¿ï¸², ºñÁøµ¿À̸í
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non REM sleep
    ³í·½¼ö¸é, Á¤»óÆÄ¼ö¸é.
  • non REM(= NREM) sleep
  • non communicating
    ºñ±³Å뼺
  • non compos mentis
    ½É½Å»ó½Ç»óÅÂ.
  • non enhanced image
    ºñÁ¶¿µ Áõ°­ ¿µ»ó
  • non hodgkin lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾(¡­ðþ)
  • non inbred
    ºñ±ÙÄ£±³¹è°è µ¿¹° .
  • non radiator
    ¹æ»ç (¿¹¹æ,Ä¡¹æ)ºñ(¼±ÅÃ)¹æ»çü.
  • non respiratory
    ºñÈ£Èí(¼º)ÀÇ.
  • non respiratory acidosis
    ºñÈ£Èí¼º »êÁõ.
  • non respiratory alkalosis
    ºñÈ£Èí¼º ¾ËÄ«¸®Áõ.
  • non secretor
    ºñºÐºñÀÚ.
  • non stress test
    ºñ±äÀ强 °Ë»ç.
  • non-Hodgkins lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • non-competitive
    ºñ°æÇÕÀû<¼º>
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FQDN Fully Qualified Domain Name
NAME Syndrome Nevi, Atrial myxoma, Myxoid neurofibroma, Ephelides Syndrome
BAN British Approved Name; British Association of Neurologists
JAN Japanese accepted name
NAME National Association of Medical Examiners; nevi, atrial myxoma, myxoid neurofibroma, ephelides [synd...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
L-NAME L-arginine and NG-nitro-L-arginine methyl ester
L-NAME N(G)-L-Arginine methyl ester
L-NAME N(G)-Nitro-L-arginine methylester hydrochloride
D-NAME N(G)-nitro-D-arginine methyl ester
NAME N(omega)-nitro-L-arginine methyl ester
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • non-dental pain
    ºñÄ¡¼º ÅëÁõ
  • non-enhanced image
    ºñÁ¶¿µ Áõ°­ ¿µ»ó
  • non-Hodgkin lymphoma
    ºñÈ£ÁöŲ ¸²ÇÁÁ¾
  • non-inflammatory
    ºñ¿°Áõ¼º
  • non-injury controlled population
    ºñ¿Ü»ó¼º ȯÀÚ
  • non-invasive
    ºñ°üÇ÷Àû, ºñħ¹ü¼º
  • non-keratinized squamous cell carcinoma
    ºñ°¢È­¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • non-malignant
    ºñ¾Ç¼º
  • non-neoplastic
    ºñ½Å»ý¹°¼º
  • non-nociceptive A delta C primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ, ºñÀ¯ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ
  • non-nociceptive cell
    ºñÄ§ÇØ ¼ö¿ë¼º ¼¼Æ÷, ºñÀ¯ÇØ ¼ö¿ë¼º ¼¼Æ÷
  • non-nociceptive myelinated afferent
    ºñÄ§ÇØ ¼ö¿ë¼º À¯¼ö ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º À¯¼ö ±¸½É ¼¶À¯
  • non-nociceptive myelinated primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯
  • non-noxious cutaneous stimulation system
    ºñÀ¯Çؼº ÇǺΠÀڱذè
  • non-odontogenic
    ºñÄ¡¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
semitrivial name A name of a chemical of which at least one part is systematic and at least one part is not (i.e., is trivial). For example, calciferol includes the -ol suffix denoting an -OH radical, while calcifer-, which has no systematic meaning, is used only in this word. Cortisone contains the -one suffix, indicating a ketone group, but the rest of the term derives from cortex (adrenal). Hippuric acid (trivial) may be defined as N-benzoylglycine (semitrivial name); benzoyl is systematic for the C6H5-CO-radical, whereas glycine is the trivial name for alpha-aminoacetic (or 2-aminoethanoic, to be completely systematic) acid, and the N signifies that the benzoyl is attached to the nitrogen of glycine; from this, the structure C6H5-CO-NH-CH2-COOH is uniquely defined. Many generic or nonproprietary names of drugs, including USAN names, hormones, etc., are semitrivial in this chemical sense, although often termed trivial names; distinction between trivial and semitrivial is not often made.
Synonym: semitrivial name.
(05 Mar 2000)
hybrid name <zoology> Names given to hybrids are not normally available, as they are individuals, not populations, and hence not taxa.
(09 Jan 1998)
NAME Acronym for nevi, atrial myxoma, myxoid neurofibromas, and ephilides.
See: NAME syndrome.
(05 Mar 2000)
name bearing type <zoology> The type genus, type species, holotype, lectotype, series of syntypes, neotype, type slide, or hapantotype, that provides the objective standard of reference whereby the application of the name of a taxon can be determined.
(09 Jan 1998)
NAME syndrome <syndrome> The concurrence of nevi, atrial myxoma, myxoid neurofibromas, and ephilides.
(05 Mar 2000)
nonproprietary name A short name (often called a generic name) of a chemical, drug, or other substance that is not subject to trademark (proprietary) rights but is, in contrast to a trivial name, recognised or recommended by government agencies (e.g., Federal Food and Drug Administration) and by quasi-official organizations (e.g., U.S. Adopted Names Council) for general public use. Like a proprietary name, it is almost always a coined designation derived without using set criteria.
Compare: trivial name, proprietary name, semisystematic name, systematic name.
(05 Mar 2000)
systematic name As applied to chemical substances, a systematic name is composed of specially coined or selected words or syllables, each of which has a precisely defined chemical structural meaning, so that the structure may be derived from the name. Water (trivial name) is hydrogen oxide (systematic). The systematic name of histamine (a semisystematic name) is imidazolethylamine, which indicates that a radical of imidazole replaces one hydrogen atom of ethylamine, which in turn is an ethyl group attached to an amine group. Dimethyl sulfoxide states that two methyl radicals are attached to a sulfur atom that holds an oxygen atom. Carbolic acid (trivial name) or phenol (semisystematic name) are, systematically, phenyl hydroxide or hydroxybenzene.
See: semisystematic name.
(05 Mar 2000)
trade name product <pharmacology> Trademarked proprietary preparations containing the generic substance. Some foreign trade name products have been selectively included here due to the relative popularity of the generic medication.
(17 Mar 1998)
trivial name A name of a chemical, no part of which is necessarily used in a systematic sense; i.e., it gives little or no indication as to chemical structure. Such names are common for drugs, hormones, proteins, and other biologicals, and are used by the general public. They may not be officially sanctioned, in contrast to nonproprietary names, but may be adopted as official nonproprietary names as a result of widespread usage. Examples are water, aspirin, chlorophyll, haem, methotrexate, folic acid, caffeine, thyroxine, epinephrine, barbital, etc.; also common abbreviations for chemically defined substances, such as ACTH, MSH, BAL, DDT, which are spoken as such and not in terms of the words they represent. The distinction between trivial and semitrivial names is seldom made; thus tetrahydrofolate, methylglycine, glucosamine, etc., are often termed trivial even though each contains a systematic part that is used in the correct systematic sense (tetrahydro for four hydrogen atoms, methyl for a -CH3 group, amine for -NH2 in the above). Trivial names are often assigned arbitrarily to chemical compounds, especially from natural sources, before the chemical structures, hence systematic names can be assigned; also, they afford useful shortenings of long systematic names even when these can be stated (although most such shortenings turn out to be semisystematic, as they incorporate some portion of the systematic name).
(05 Mar 2000)
abortifacient agents, non-steroidal Non-steroidal chemical compounds with abortifacient activity.
(12 Dec 1998)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
analgesics, non-narcotic Drugs that have principally analgesic, antipyretic, and anti-inflammatory actions. They do not bind to opioid receptors and are not classified under the controlled substances act.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
auctorum non Not of authors.
(09 Jan 1998)
cancer, lymphoma, non-hodgkin's A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non est inventus
    º»ÀμÒÀç ºÒ¸í
  • non liquet
    ÀçÆÇ ¿¬±âÀÇ ¹è½ÉÆò°á
  • non obs(t).
    non obstante
  • non obstante
    ..¿¡µµ ºÒ±¸Çϰí
  • non placet
    (±³È¸,´ëÇÐÀÇ Áýȸ¿¡¼­)ÀÌÀÇ;¹Ý´ëÅõÇ¥
  • non plus ultra
    NE PLUS ULTRA
  • non possumus
    ¹«´É·Â(ºÒ´É)ÀÇ ½Åû
  • non prosequitur
    (¼Ò¼ÛÀýÂ÷¸¦ Ÿ¸È÷ ÇÏ´Â ¿ø°í¿¡ ´ëÇÑ)ÆÐ¼ÒÆÇ°á
  • non seq.
    non sequitur
  • non sequitur
    ±×¸©µÈ °á·Ð
  • non troppo
    Áö³ªÄ¡Áö ¾Ê°Ô;¾Ë¸Â°Ô
  • non-
    ¾Ê´Ù;¾Æ´Ï´Ù
  • non-
    (ÀÚÀ¯·ÎÀÌ ¸í»ç,Çü¿ë»ç,ºÎ»ç¿¡ ºÙ¿©¼­);ºñ;ºÒ;¹«ÀÇ ¶æÀ» ³ªÅ¸³¿
  • sine qua non
    ÇÊ¿ä Á¶°Ç
  • by-name
    º°¸í
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á